1. Home
  2. DSAC vs VCRE Comparison

DSAC vs VCRE Comparison

Compare DSAC & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Daedalus Special Acquisition Corp. Class A Ordinary Shares

DSAC

Daedalus Special Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$10.17

Market Cap

345.6M

Sector

Finance

ML Signal

N/A

Logo Vicore Pharma Holding AB American Depositary Shares

VCRE

Vicore Pharma Holding AB American Depositary Shares

N/A

Current Price

$10.03

Market Cap

316.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DSAC
VCRE
Founded
2025
N/A
Country
United Kingdom
Sweden
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
345.6M
316.4M
IPO Year
2025
2026

Fundamental Metrics

Financial Performance
Metric
DSAC
VCRE
Price
$10.17
$10.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
238.2K
10.3K
Earning Date
01-01-0001
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.90
$10.16
52 Week High
$10.47
$13.15

Technical Indicators

Market Signals
Indicator
DSAC
VCRE
Relative Strength Index (RSI) 50.26 35.77
Support Level $9.90 N/A
Resistance Level $10.18 $13.00
Average True Range (ATR) 0.01 0.54
MACD -0.00 -0.11
Stochastic Oscillator 16.67 14.15

Price Performance

Historical Comparison
DSAC
VCRE

About DSAC Daedalus Special Acquisition Corp. Class A Ordinary Shares

Daedalus Special Acquisition Corp is a blank check company.

About VCRE Vicore Pharma Holding AB American Depositary Shares

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

Share on Social Networks: